UPDATE: Nkarta touts a double dose of data for natural killer cell therapiesnews2022-04-25T14:35:42+00:00April 25th, 2022|FierceBiotech|
Phase 2 deja vu for gossamer bio after ulcerative colitis med flopsnews2022-04-25T14:27:01+00:00April 25th, 2022|FierceBiotech|
Weeks after Sanofi flop, Roche’s rival breast cancer drug flunks phase 2 testnews2022-04-25T07:55:53+00:00April 25th, 2022|FierceBiotech|
Agilex Biolabs Doubles in Size with Launch of New Large Molecule Facility as It Expands Its U.S. Presencenews2022-04-22T17:41:46+00:00April 22nd, 2022|FierceBiotech|
Vallon looks for escape route a month after sole clinical asset fails in clinicnews2022-04-22T14:55:24+00:00April 22nd, 2022|FierceBiotech|
Astellas takes $170M hit as DMD gene therapy plan unravels in wake of preclinical datanews2022-04-22T11:47:46+00:00April 22nd, 2022|FierceBiotech|
The Clever-1? Faron hails melanoma data despite lack of responsesnews2022-04-22T09:26:25+00:00April 22nd, 2022|FierceBiotech|
Chutes & Ladders—Romanelli returns to Merck to lead international human health team after brief CEO stintnews2022-04-21T21:51:17+00:00April 21st, 2022|FierceBiotech|
Bayer nabs yet another oncology leader from GSK to bolster cancer effortsnews2022-04-21T19:45:40+00:00April 21st, 2022|FierceBiotech|
Novavax executives’ pay comes back down to Earth after 8-figure package in 2020news2022-04-21T18:41:52+00:00April 21st, 2022|FierceBiotech|
